Future Perspectives and Unmet Needs in the Treatment of Ovarian Cancer
Chad A. Hamilton, MD, offers closing thoughts on the future outlook and unmet needs in the ovarian cancer treatment landscape.
Recent Data Updates from PRIMA and PAOLA-1 Trials in Ovarian Cancer
Key takeaways from recent data updates from the PRIMA and PAOLA-1 trials investigating PARP inhibitors in ovarian cancer.
Ovarian Cancer: Strategies for Managing GI Toxicities and Fatigue from PARP Inhibitors
Chad A. Hamilton, MD, shares strategies for managing gastrointestinal toxicities and fatigue for patients receiving PARP inhibitors for the treatment of ovarian cancer.
Adverse Events from PARP Inhibitors in Ovarian Cancer
Clinical insights on adverse effects seen with PARP inhibitors in the treatment of patients with ovarian cancer.
Considerations for Initiating Maintenance Therapy in Ovarian Cancer
An overview of factors that influence the initiation of maintenance therapy for patients with ovarian cancer.
Informing Ovarian Cancer Treatment Approach With Clinical Trial Data
Chad A. Hamilton, MD, discusses how clinical trial data inform treatment selection for patients with ovarian cancer.
Maintenance Therapy Landscape for Frontline Ovarian Cancer
A comprehensive overview of the maintenance therapy landscape in ovarian cancer, with a focus on clinical trials investigating bevacizumab, olaparib, and niraparib.
Overview of Guideline Recommendations for Molecular Testing in Ovarian Cancer
An expert gynecologic oncologist reviews guideline recommendations for molecular testing in ovarian cancer and shares his testing practices.
Patient Profile: A 49-Year-Old Woman with BRCA Wild-Type Ovarian Cancer
Chad A. Hamilton, MD, presents the case of a 49-year-old woman with BRCA wild-type ovarian cancer and offers his initial impressions.
2 Clarke Drive Cranbury, NJ 08512